Dmitrii Tsypyshev

Mr. Dmitrii Tsypyshev

Bashkir State University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMikhail Voronin
Mikhail Voronin
YVYulia Vakhitova
Yulia Vakhitova
ITInna Tsypysheva
Inna Tsypysheva
DTDmitrii Tsypyshev
Dmitrii Tsypyshev
IRInna V. Rybina
Inna V. Rybina
SSSergei B. Seredenin
Sergei B. Seredenin
Sigma-1 receptor (chaperone Sigma1R) is an intracellular protein with chaperone functions, which is expressed in various organs, including the brain. Sigma1R participates in the regulation of physiological mechanisms of anxiety (Su, T. P. et al., 2016) and reactions to emotional stress (Hayashi, T., 2015). In 2006, fabomotizole (ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride) was registered in Russia as an anxiolytic (Seredenin S. and Voronin M., 2009). The molecular targets of fabomotizole are Sigma1R, NRH: quinone reductase 2 (NQO2), and monoamine oxidase A (MAO-A) (Seredenin S. and Voronin M., 2009). The current study aimed to clarify the dependence of fabomotizole anxiolytic action on its interaction with Sigma1R and perform a docking analysis of fabomotizole interaction with Sigma1R. An elevated plus maze (EPM) test revealed that the anxiolytic-like effect of fabomotizole (2.5 mg/kg i.p.) administered to male BALB/c mice 30 min prior EPM exposition was blocked by Sigma1R antagonists BD-1047 (1.0 mg/kg i.p.) and NE-100 (1.0 mg/kg i.p.) pretreatment. Results of initial in silico study showed that fabomotizole locates in the active center of Sigma1R, reproducing the interactions with the site’s amino acids common for established Sigma1R ligands, with the ΔGbind value closer to that of agonist (+)-pentazocine in the 6DK1 binding site.

8 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Margarita NeganovaMargarita Neganova
Margarita Neganova
YAYulia Aleksandrova
Yulia Aleksandrova
ESEvgenii Suslov
Evgenii Suslov
EMEvgenii Mozhaitsev
Evgenii Mozhaitsev
AMAldar Munkuev
Aldar Munkuev
SKSergey Klochkov
Sergey Klochkov
Hydroxamic acids are one of the most promising and actively studied classes of chemical compounds in medicinal chemistry. In this study, we describe the directed synthesis and effects of HDAC6 inhibitors. Fragments of adamantane and natural terpenes camphane and fenchane, combined with linkers of various nature with an amide group, were used as the CAP groups. Accordingly, 11 original target compounds were developed, synthesized, and exposed to in vitro and in vivo biological evaluations, including in silico methods. In silico studies showed that all synthesized compounds were drug-like and could penetrate through the blood–brain barrier. According to the in vitro testing, hydroxamic acids 15 and 25, which effectively inhibited HDAC6 and exhibited anti-aggregation properties against β-amyloid peptides, were chosen as the most promising substances to study their neuroprotective activities in vivo. All in vivo studies were performed using 5xFAD transgenic mice simulating Alzheimer’s disease. In these animals, the Novel Object Recognition and Morris Water Maze Test showed that the formation of hippocampus-dependent long-term episodic and spatial memory was deteriorated. Hydroxamic acid 15 restored normal memory functions to the level observed in control wild-type animals. Notably, this effect was precisely associated with the ability to restore lost cognitive functions, but not with the effect on motor and exploratory activities or on the level of anxiety in animals. Conclusively, hydroxamic acid 15 containing an adamantane fragment linked by an amide bond to a hydrocarbon linker is a possible potential multitarget agent against Alzheimer’s disease.

1 May 2019 in Tetrahedron
Verified
Journal Article
Closed access
ITInna Tsypysheva
Inna Tsypysheva
AKAlena Koval'SKaya
Alena Koval'SKaya
PPPolina Petrova
Polina Petrova
ALAlexander N. Lobov
Alexander N. Lobov
Sophia S. BorisevichSophia S. Borisevich
Sophia S. Borisevich
VZVladimir Zarubaev
Vladimir Zarubaev

Verified
Journal Article
Open access
PDF file
EGElmira Mingaleevna Gibadullina
Elmira Mingaleevna Gibadullina
Margarita NeganovaMargarita Neganova
Margarita Neganova
YAYulia Aleksandrova
Yulia Aleksandrova
NTNguyen Hoang Bao Tran
Nguyen Hoang Bao Tran
AVAlexandra Voloshina
Alexandra Voloshina
Igor V. AlabuginIgor V. Alabugin
Igor V. Alabugin
The utility of sterically hindered phenols (SHPs) in drug design is based on their chameleonic ability to switch from an antioxidant that can protect healthy tissues to highly cytotoxic species that can target tumor cells. This work explores the biological activity of a family of 45 new hybrid molecules that combine SHPs equipped with an activating phosphonate moiety at the benzylic position with additional urea/thiourea fragments. The target compounds were synthesized by reaction of iso(thio)cyanates with C-arylphosphorylated phenols containing pendant 2,6-diaminopyridine and 1,3-diaminobenzene moieties. The SHP/urea hybrids display cytotoxic activity against a number of tumor lines. Mechanistic studies confirm the paradoxical nature of these substances which combine pronounced antioxidant properties in radical trapping assays with increased reactive oxygen species generation in tumor cells. Moreover, the most cytotoxic compounds inhibited the process of glycolysis in SH-SY5Y cells and caused pronounced dissipation of the mitochondrial membrane of isolated rat liver mitochondria. Molecular docking of the most active compounds identified the activator allosteric center of pyruvate kinase M2 as one of the possible targets. For the most promising compounds, 11b and 17b, this combination of properties results in the ability to induce apoptosis in HuTu 80 cells along the intrinsic mitochondrial pathway. Cyclic voltammetry studies reveal complex redox behavior which can be simplified by addition of a large excess of acid that can protect some of the oxidizable groups by protonations. Interestingly, the re-reduction behavior of the oxidized species shows considerable variations, indicating different degrees of reversibility. Such reversibility (or quasi-reversibility) suggests that the shift of the phenol-quinone equilibrium toward the original phenol at the lower pH may be associated with lower cytotoxicity.

19 January 2024 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CLChen-Sheng Lin
Chen-Sheng Lin
CLChih-Hao Lu
Chih-Hao Lu
TLTsai-Hsiu Lin
Tsai-Hsiu Lin
YKYan-Tung Kiu
Yan-Tung Kiu
JKJu-Ying Kan
Ju-Ying Kan
Cheng-Wen LinCheng-Wen Lin
Cheng-Wen Lin

Verified
Journal Article
Open access
PDF file
YAYulia Aleksandrova
Yulia Aleksandrova
AMAldar Munkuev
Aldar Munkuev
EMEvgenii Mozhaitsev
Evgenii Mozhaitsev
ESEvgenii Suslov
Evgenii Suslov
DTDmitrii Tsypyshev
Dmitrii Tsypyshev
Margarita NeganovaMargarita Neganova
Margarita Neganova
Novel monoterpene-based hydroxamic acids of two structural types were synthesized for the first time. The first type consisted of compounds with a hydroxamate group directly bound to acyclic, monocyclic and bicyclic monoterpene scaffolds. The second type included hydroxamic acids connected with the monoterpene moiety through aliphatic (hexa/heptamethylene) or aromatic linkers. An in vitro analysis of biological activity demonstrated that some of these molecules had powerful HDAC6 inhibitory activity, with the presence of a linker area in the structure of compounds playing a key role. In particular, it was found that hydroxamic acids containing a hexa- and heptamethylene linker and (-)-perill fragment in the Cap group exhibit excellent inhibitory activity against HDAC6 with IC50 in the submicromolar range from 0.56 ± 0.01 µM to 0.74 ± 0.02 µM. The results of the study of antiradical activity demonstrated the presence of moderate ability for some hydroxamic acids to scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2ROO• radicals. The correlation coefficient between the DPPH radical scavenging activity and oxygen radical absorbance capacity (ORAC) value was R2 = 0.8400. In addition, compounds with an aromatic linker based on para-substituted cinnamic acids, having a monocyclic para-menthene skeleton as a Cap group, 35a, 38a, 35b and 38b, demonstrated a significant ability to suppress the aggregation of the pathological β-amyloid peptide 1-42. The 35a lead compound with a promising profile of biological activity, discovered in the in vitro experiments, demonstrated neuroprotective effects on in vivo models of Alzheimer’s disease using 5xFAD transgenic mice. Together, the results obtained demonstrate a potential strategy for the use of monoterpene-derived hydroxamic acids for treatment of various aspects of Alzheimer’s disease.